Effects of lesopitron on the central nervous system arising from its interaction with 5-HT1A receptors

Pharmacology

Volumn 72, Issue 2, 2004, Pages 57-67

  Fisas, M Angels ^a   Farré, Antonio ^a   Camarasa, Jorge ^b   Escubedo, Elena ^b  

^a Laboratorios Dr Esteve SA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

5 HT1A receptors; 8 OH DPAT; Hypothermia; Lesopitron

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AUTORECEPTOR; HALOPERIDOL; LESOPITRON; PAROXETINE; RECEPTOR SUBUNIT; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HYPOTHERMIA; MALE; MOLECULAR INTERACTION; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; SEROTONIN SYNDROME; SEROTONIN UPTAKE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; CATALEPSY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DRUG INTERACTIONS; FEMALE; HIPPOCAMPUS; HYPOTHERMIA; LIGANDS; MALE; MICE; PAROXETINE; PIPERAZINES; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY;

EID: 4444354036     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079133     Document Type: Article

References (39)

1. Boyer WF, Feighner JP: A placebo-controlled double-blind multicenter trial of two doses of ipsapirone vs. diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 1993;8: 173-176.
2. Cutler NR, Sramek JJ, Keppel JM, Krol A, Roeschen J, Rickels K, Schweizer E: A doubleblind, placebo-controlled study comparing the efficacy and safety of ipsapirone vs. lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial. J Clin Psychopharmacol 1993;13:429-437.
3. Goldberg HL, Finerty R: Comparison of buspirone in two separate studies. J Clin Psychiatry 1982;43:87-91.
4. 1A receptors. Chicester, Horwood, 1987, pp 67-81.
5. Plassat JL, Amlaiky N, Hen R: Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol 1993;44:220-236.
6. 2) agonists and antagonists on rennin and corticosterone secretion. Neuroendocrinology 1987;45:305-310.
7. 1A receptor agonist 8-hydroxy-2-(-di-n-propylamino)tetralin. Pharmacol Biochem Behav 1989;33:329-334.
8. 1A receptor agonist, 8-OH-DPAT preferentially activates cell body 5-HT autoreceptors in rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1988;338:463-471.
9. Hjorth S: Hypothermia in the rat induced by the potent serotonergic agent 8-OH-DPAT. J Neural Transm 1985;61:131-135.
10. 1A receptor activation. Br J Pharmacol 1992;106:603-606.
11. Lucki I: 5-HT1 receptors and behaviour. Biobehav Rev 1992;16:83-93.
12. 1A receptor; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 1301-1310.
13. 1A receptor antagonist, in the murine elevated plus-maze. Psychopharmacology (Berl) 1997;129:365-371.
14. Engel JA, Hjorth S, Svensson K, Carlsson A, Liljequist S: Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Eur J Pharmacol 1984;105:365-368.
15. 1A receptor agonist 8-OH-DPAT. Neuropharmacology 1990;29:85-91.
16. Goodwin GM, De Souza RJ, Green AR, Heal DJ: The pharmacology of the behavioral and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Psychopharmacology 1987;91:500-505.
17. 1A agonists LY-65163 and 8-OH-DPAT is not prevented by 5-HT depletion. Eur J Pharmacol 1987;143:221-228.
18. Costall B, Domemey AM, Farre AF, Kelly FM, Martinez L, Naylor RJ: Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. J. Pharmacol Exp Ther 1992;262:90-98.
19. 1A receptors: In vitro and in vivo studies in the rat. Eur J Pharmacol 1994;255:185-196.
20. Harkany T, Mulder J, Horvath KM, Keijser J, van der Meeberg EK, Nyakas C, Luiten PG: Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAY x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience 2001;108:629-642.
21. Torup L, Moller A, Sager TN, Diemer NH: Neuroprotective effect of 8-OH-DPAT in global cerebral ischemia assessed by stereological cell counting. Eur J Pharmacol 2000;395:137-141.
22. 1A receptors. II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 1997;282:148-161.
23. McMillen BA, Scott SM, Davanzo EA: Reversal of neuroleptic-induced catalepsy by a novel arylpiperazine anxiolytic drug. J Pharm Pharmacol 1988;40:885-887.
24. Sanberg PR, Bunsey MD, Giordano M, Norman AB: The catalepsy test, its ups and downs. Behav Neurosci 1988;102:748-759.
25. 3H]dopa in various regions of the brain. J Neurochem 1996;13:655-669.
26. Nelson DL, Herbert S, Bourgoin J, Glowinski J, Hamon M: Characteristics of central 5-HT receptors and their adaptative changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 1978; 14:983-995.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
28. 1A Receptors. Chicester, Horwood, 1987, pp 261-277.
29. Wilkinson LO, Dourish CT: Serotonin and animal behaviour; in Peroutka SJ (ed): Serotonin Receptor Subtypes: Basic and Clinical Aspects. Receptor Biochemistry and Methodology. New York, Wiley-Liss, 1990, vol 15, pp 147-210.
30. Deakin JFW, Green AR: The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by the administration of tranylcypromine and L-tryptophan or tranylcypromine and L-dopa to rats. Br J Pharmacol 1978;64:201-209.
31. Trulson ME, Eubanks EE, Jacobs BL: Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther 1976;198:23-32.
32. Prinssen EP, Koek W, Kleven MS: Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: A role for tonic activation of 5-HT(1A) receptors. Eur J Pharmacol 2000;395:143-147.
33. Invernizzi RW, Cervo L, Samanin R: 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 1988;27:515-518.
34. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 1995;34:495-499.
35. Zuideveld KP, Rusiç-Pavletiç J, Maas HJ, Peletier LA, Van der Graaf PH, Danhof M: Pharmacokinetic-Pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidyl)piperazine in rats. J Pharmacol Exp Ther 2002;303:1130-1137.
36. 1A agonist, 8-OH-DPAT. Pharmacol Biochem Behav 1992;43:953-955.
37. Blier P, Seletti B, Gilbert F, Young SN, Benkelfat C: Serotonin 1A receptor activation and hypothermia in humans: Lack of evidence for a presynaptic mediation. Neuropsychopharmacology 2002;27:301-308.
38. A receptor-chloride channel complex. Pharmacol Toxicol 2002;90:14-19.
39. 1A receptor agonist 8-OH-DPAT. Eur J Pharmacol 1998;358:147-152.